Finally, it is important to note that the prior CCS cardiorenal guideline committee did not feel that recommendations regarding either HF or CKD protection using GLP1-RA were warranted in the absence of published, dedicated trials in these populations. This evidence concerns the gene GLP1R and chronic kidney disease.